Are You Doing Serious Work?

Are You Doing Serious Work?

While ploughing through some to-do list items on my laptop, my five-year old came by to complain about being bored. I asked her to help me by drawing out her day on some graph paper. She happily framed out storyboards and began the process of putting her life to pictures.

Rough and childlike, her illustrations were exactly what you are imagining right now. Interestingly though, her drawings reminded me of Paula Scher, a renowned graphic designer and visual artist. You know her work, even if you’ve never heard her name before. She created the Citigroup logo, the original Windows logo and the incredible typographical artwork for the Bloomberg Building in NYC. Her work is multidimensional and profoundly unique but when she begins a project, her work is wonderfully rough and decidedly childlike.

This is the original concept for the Citigroup logo.

Russell Baker serious work mineral interactive

Maybe you can see why my daughter’s sketches reminded me of her work. The first time I saw her rough work, I was impressed by the lack of sophistication. There is a strong element of play when doing creative work that she, rather obviously, embraces.

Play can be a hard concept for us to understand as adults, but it boils down to the idea of creating without regard for strict practicality. Play might not seem like a thing you do much at work. While it’s true that you might not be creating your own logo (we highly suggest you don’t), you are doing creative work every day. Every time you sit down to solve a problem, offer a solution, or build out a plan for a client, you’re using creativity. To be clear, play doesn’t mean whimsy and it doesn’t mean this element of your work isn’t serious.

In her 2008 TEDtalk, Ms. Scher explained a truth about how play and work intersect that has a broad application. She quotes an article from Russell Baker that sets up a dichotomy between serious work and solemn work. Here’s an excerpt for you to see both his humor about it and the point he is making:

Being solemn is easy. Being serious is hard…Children almost always begin by being serious, which is what makes them so entertaining when compared to adults as a class. Adults, on the whole are solemn.

Jogging is solemn. Poker is serious.

Humphrey Bogart movies about private eyes and Randolph Scott movies about gunslingers are serious. Modern movies that are sophisticated jokes about Humphrey Bogart movies and Randolph Scott movies are solemn.

Solemnity is taking yourself too seriously – it’s producing work separate from your own emotion, or focusing only on a desired outcome instead of opening yourself to the possibility of all that could be. Solemn work is rote, draining, and stale, albeit reliable.

Serious work is focused and exciting. It requires a freshness and vitality that solemn work cannot stand. Serious work can be funny and uniquely you.

Your clients and potential clients need you to be serious but not solemn. They need you to see them as individuals who need your personality and expertise. When you give them your serious work, they get to build a relationship with you. If you merely give them solemn work, they may receive the same portfolio and outcomes, but they won’t get the part that will keep them there for years to come.

What do you need in order to do serious work? In large part, the answer is downtime. You need space and margin enough to conjure up fresh ideas, to take all of the important things swimming in your brain and dial them into fresh solutions. You need a mental break from the demands of media. To do this serious work, you’re going to need to schedule breaks small and large so that you can come back free of solemnity.

How are you freeing yourself from solemn work this summer?

  • Time at the lake?
  • A big trip out of town?
  • Evening walks through your neighborhood?
Jud Mackrill
Digital Marketing
Twitter Email

Jud Mackrill serves as the Cofounder of Mineral. At Mineral, his focus is helping investment advisory businesses focus on growing digitally through full-scale design, brand de ... Click for full bio

How We're Investing in the Search for a Cancer Cure

How We're Investing in the Search for a Cancer Cure

Written by: Frank Jennings, Ph.D., Portfolio Manager

I hate cancer.

I’ve lost one too many friends to this insidious disease and I’ve made it a priority to be part of the effort to find a cure for it. Every day, I draw motivation from the people I’ve lost in my work as Portfolio Manager of Oppenheimer Global Opportunities Fund.

I may not be a doctor or medical industry professional, but the work my team and I do has brought us to the front lines of the ongoing fight against cancer. The Fund’s guiding philosophy is to invest in emergent growth companies that we believe have the potential to grow into large, highly profitable businesses.

Our search for these types of companies has given me renewed hope that we are closer than ever to finding a cure for one of the deadliest scourges humanity has ever known.

OppenheimerFunds’ Role in the Fight

Oppenheimer Global Opportunities Fund invests in a number of pharmaceutical and biotechnology companies that are developing breakthrough drugs that can potentially treat the disease more effectively without debilitating side effects, make it easier for patients to manage pain, and possibly even lower the cost of treatment.

The cutting-edge therapies that are in development may even pave the way to the ultimate goal – a cure for all forms of the disease. Of course, one glance at the National Cancer Institute (NCI) website is all it takes to remind us we’re in a fight that often feels like an uphill race against time.

At some point in their lifetime, nearly 40% of the population will be diagnosed with cancer, according to the NCI. Last year in the United States alone, 1.7 million people received this dreaded news from their doctor, while nearly 600,000 people succumbed to the disease.1

These statistics certainly make it fair to ask why I’m so optimistic about the future of cancer treatment and the potential for a cure.

Well for starters, just consider that geneticists have finally mapped the entire human genome. Today, 100 million people have had their genomes mapped, which has enabled us to confirm, for example, that there is a particular gene mutation that places some women at a high risk of developing breast or ovarian cancer at some point in their life.

This is important on several fronts. First, it allows doctors to know beforehand whether or not a cancer drug will work on a patient due to the genetic makeup of the cancer. This means fewer drugs will be prescribed inappropriately. It may even help bring promising new treatments to market faster.

By knowing a cancer’s genetic makeup, drug trials can be conducted only on people with a high probability of success. In turn, this will result in less money wasted, better outcomes for patients, and ultimately, faster approvals by the U.S. Food and Drug Administration (FDA) and other international regulatory bodies.

The Biotechnology and Pharmaceutical Companies We Believe In

One of the largest holdings in the portfolio is in a company that develops and markets therapies that mimic a person’s own immune system to fight cancer. This particular company, which is headquartered in the U.S., recently developed a new antibody-drug conjugate (ADC) technology that allows its medications to attack cancer cells with fewer side effects than chemotherapy.

This firm has a number of innovative cancer medications at its disposal – including therapies for treating various types of lymphoma. The company continues to sign partners onto its proprietary ADC technology, and we believe it is well-positioned to earn millions in royalties over the long term, making it an attractive acquisition target for larger drug makers. 

There are a number of European pharmaceutical and biotech firms in the portfolio as well, including another company that specializes in immunotherapy – which seeks to boost the body’s immune system to fight off cancer.

Analysts have predicted this company’s treatment for multiple myeloma has blockbuster potential. And although the drug is primarily used to fight blood cancer, there are signs that it could also work against solid tumors as well. Now beyond the “cash-burning stage” that afflicts most drug makers at some point, this company is on track to becoming a mature biotech firm that’s positioned for strong overall sales and steady royalty income in the near future.

Over the last five years, shares of this company have climbed more than 2,000% and we see potential for continued strong future growth.

How the Cancer Fight Aligns with My Investment Philosophy

I believe companies have a lifecycle – just like people do. There’s a beginning, adolescence, prime years, and an eventual decline phase. Companies usually begin as entrepreneurial ventures powered by the spirit of a startup. If they’re successful, they gradually mature into corporate entities and can enjoy an extended run of success. The decline phase typically takes root when companies get too big and bogged down by bureaucracy, regulation and saturated markets.

The Fund seeks to invest in businesses that still have exponential growth ahead of them. I’ve been excited to discover that there are quite a few companies like this at the forefront of the fight against cancer. Investing in these types of companies within the Oppenheimer Global Opportunities Fund can help clients achieve their desired investment outcomes, which is my top priority as a portfolio manager.

Combining this core mission with my personal desire to see cancer eradicated is one of the most gratifying parts of my job.

Learn more about how we think about investments differently, visit

Foreign investments may be volatile and involve additional expenses and special risks, including currency fluctuations, foreign taxes, regulatory and geopolitical risks. Emerging and developing market investments may be especially volatile. Eurozone investments may be subject to volatility and liquidity issues. Investments in securities of growth companies may be volatile. Mid-sized company stock is typically more volatile than that of larger company stock. It may take a substantial period of time to realize a gain on an investment in a mid-sized company, if any gain is realized at all. Fixed income investing entails credit and interest rate risks. When interest rates rise, bond prices generally fall, and the Fund’s share prices can fall. Below-investment-grade (“high yield” or “junk”) bonds are more at risk of default and are subject to liquidity risk. Diversification does not guarantee profit or protect against loss.

Mutual funds and exchange traded funds are subject to market risk and volatility. Shares may gain or lose value.

These views represent the opinions of OppenheimerFunds, Inc. and are not intended as investment advice or to predict or depict the performance of any investment. These views are as of the publication date, and are subject to change based on subsequent developments.

Carefully consider fund investment objectives, risks, charges, and expenses. Visit or call your advisor for a prospectus with this and other fund information. Read it carefully before investing. 

OppenheimerFunds is not affiliated with

©2017 OppenheimerFunds Distributor, Inc.

Explore Investment Insights
Twitter Email

OppenheimerFunds, Inc., a leader in global asset management, is dedicated to providing solutions for its partners and end investors. OppenheimerFunds, including its subsidiari ... Click for full bio